EGLN1
Egl nine homolog 1
As of the edition of 20 October 2026, EGLN1 (egl nine homolog 1, UniProt Q9GZT9) has 5 drugs tested at it and 12 companies on the list, 0 on route A and 5 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9GZT9
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 67
- Disease areas
- Blood and lymph; Pregnancy and women's health; Urinary and reproductive; Heart and blood vessels; Hormones; Infections; Lungs and airways; Nervous system
- Registered trials of its drugs
- 171
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Roxadustat | Marketed | Phase 4 | none listed |
| Daprodustat | Marketed | Phase 4 | Ends 2038 |
| Vadadustat | Marketed | Phase 4 | Ends 2034 |
| Molidustat | Marketed | Phase 3 | none listed |
| Enarodustat | Marketed | Phase 4 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 5 |
| Engaged | 4 |
| Undetermined | 3 |
| Total on the list | 12 |
| Company | Route |
|---|---|
| GSK | Route B |
| Akebia Therapeutics | Route B |
| Medice Arzneimittel Pütter | Route B |
The other 9 companies at EGLN1
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at EGLN1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.